ArticleCancer cell2023
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Pooled it
- Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Trial
- Urine cell-free RNA for bladder cancer detection and treatment response prediction.Nature medicine · 2026Article
- Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.European journal of nuclear medicine and molecular imaging · 2026Article
- Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood advances · 2026Review
- RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR-T Resistant Large B-cell Lymphomas.Blood cancer discovery · 2026Article
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Review
- Feasibility and safety of rapid glofitamab ramp-up.Leukemia · 2026Article
- Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature Review.Journal of clinical medicine · 2026Review
- A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.Leukemia · 2026Article
- Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy.Blood science (Baltimore, Md.) · 2026Article
- Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.Blood advances · 2026Article
- Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.HemaSphere · 2026Article
- Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma.Journal of medical cases · 2026Article
- Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells.Molecular therapy. Oncology · 2026Article
- The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies.Biochimica et biophysica acta. Reviews on cancer · 2026Review
- A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.bioRxiv : the preprint server for biology · 2026Article
- A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma.Blood cancer discovery · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
36 authors at 7 institutions in 2 countries.
Brian J SworderDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
David M KurtzDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Stefan K AligDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Matthew J FrankDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA.
Navika ShuklaDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Andrea GarofaloDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Charles W MacaulayDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Mohammad Shahrokh EsfahaniDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Mari N OlsenDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
James HamiltonDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Hitomi HosoyaDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Mark HamiltonDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jay Y SpiegelDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA.
John H BairdDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA.
Takeshi SugioDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Mia CarletonDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Alexander F M CraigDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Sheren F YounesDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Bita SahafDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA.
Natasha D SheybaniDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Joseph G Schroers-MartinDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Chih Long LiuDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Jean S OakDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Michael C JinDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Sara BeygiDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA.
Andreas HüttmannDepartment of Hematology, University Hospital of Essen, Essen, Germany.
Christine HanounDepartment of Hematology, University Hospital of Essen, Essen, Germany.
Ulrich DührsenDepartment of Hematology, University Hospital of Essen, Essen, Germany.
Jason R WestinDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael S KhodadoustDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA.
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Robbie G MajznerCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA; Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Crystal L MackallCenter for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA; Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, Stanford University School of Medicine, Stanford, CA 94305, USA.
Maximilian DiehnStanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA.
David B MiklosDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford, CA 94305, USA.
Ash A AlizadehDivision of Oncology, Department of Medicine, Stanford University, 265 Campus Drive, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: arasha@stanford.edu.
Stanford University · USStanford Blood Center · USEssen University Hospital · DECalifornia Institute for Regenerative Medicine · USStanford Medicine · USParker Institute for Cancer Immunotherapy · USThe University of Texas MD Anderson Cancer Center · US
Funding
TUMOR SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN BONE MARROW TRANSPLANTATIONP01CA049605 · NCI · STANFORD UNIVERSITY · PI David B. Miklos, Robert S Negrin · 1989 to 2026
$73.3MCirculating Genomic Determinants of Treatment Failure in Hodgkin LymphomaR01CA257655 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2021 to 2025
$3.2MAnalysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerR01CA244526 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.0MA Noninvasive Integrated Genomic Approach for Early Cancer Detection and Risk Stratification after TransplantationR01CA229766 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, KHUSH, KIRAN KAUR · 2019 to 2023
$3.0MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MMolecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNAK08CA241076 · NCI · STANFORD UNIVERSITY · PI KURTZ, DAVID MATTHEW · 2019 to 2023
$957kLymphoma Antigen Density and Circulating Tumor DNA Profiling As Determinants of Novel CAR TherapiesK08CA248968 · NCI · STANFORD UNIVERSITY · PI FRANK, MATTHEW J. · 2020 to 2024
$845kFocused Ultrasound and Multifunctional Nanoparticle Vaccines as Adjuvant Strategies for Cancer ImmunotherapyK00CA234954 · NCI · STANFORD UNIVERSITY · PI SHEYBANI, NATASHA DIBA · 2020 to 2021
$183kNCI NIH HHS K00 CA234954NCI NIH HHS K08 CA241076NCI NIH HHS K08 CA248968NCI NIH HHS P01 CA049605NCI NIH HHS R01 CA229766NCI NIH HHS R01 CA233975NCI NIH HHS R01 CA244526NCI NIH HHS R01 CA257655
Abstract
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of resistance, we profiled over 700 longitudinal specimens from two independent cohorts (n = 65 and n = 73) of r/rLBCL patients treated with axicabtagene ciloleucel. A method for simultaneous profiling of circulating tumor DNA (ctDNA), cell-free CAR19 (cfCAR19) retroviral fragments, and cell-free T cell receptor rearrangements (cfTCR) enabled integration of tumor and both engineered and non-engineered T cell effector-mediated factors for assessing treatment failure and predicting outcomes. Alterations in multiple classes of genes are associated with resistance, including B cell identity (PAX5 and IRF8), immune checkpoints (CD274), and those affecting the microenvironment (TMEM30A). Somatic tumor alterations affect CAR19 therapy at multiple levels, including CAR19 T cell expansion, persistence, and tumor microenvironment. Further, CAR19 T cells play a reciprocal role in shaping tumor genotype and phenotype. We envision these findings will facilitate improved chimeric antigen receptor (CAR) T cells and personalized therapeutic approaches.
Indexed as
Lymphoma, Large B-Cell, DiffuseReceptors, Chimeric AntigenAntigens, CD19HumansImmunotherapy, AdoptiveNeoplasm Recurrence, LocalT-LymphocytesTumor MicroenvironmentAntigens, CD19Receptors, Chimeric Antigencell-free DNAchimeric antigen receptor T cellscirculating tumor DNActDNAgenomicsimmunotherapylarge B cell lymphomaMRDoncologyprecision medicine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.